Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Rosmarin, David [1 ]
Lebwohl, Mark [2 ]
Feldman, Steven R. [3 ]
Staubach-Renz, Petra [4 ]
Davis, Leah [5 ]
Wixted, Krista [5 ]
Madden, Cynthia [5 ]
Gomez, Natalie Nunez [6 ]
Pinter, Andreas [7 ]
机构：
[1] Tufts Med Ctr, Dept Dermatol, Boston, MA USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Wake Forest Sch Med, Dept Dermatol, Winston Salem, NC USA
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Mainz, Germany
[5] UCB Pharma, Raleigh, NC USA
[6] UCB Pharma, Brussels, Belgium
[7] Univ Hosp Frankfurt, Frankfurt, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
34320
引用
收藏
页码：AB146 / AB146
页数：1
相关论文
共 50 条
  • [1] Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
    Ruggiero, Angelo
    Potestio, Luca
    Martora, Fabrizio
    Villani, Alessia
    Comune, Rosita
    Megna, Matteo
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (05) : 355 - 362
  • [2] COMPARATIVE EFFICACY OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
    Armstrong, A.
    Reich, K.
    Warren, R. B.
    Taieb, V
    Fahrbach, K.
    Kazmierska, P.
    Betts, M.
    Neupane, B.
    Kiri, S.
    Gordon, K.
    [J]. VALUE IN HEALTH, 2021, 24 : S14 - S14
  • [3] BUDGET IMPACT ANALYSIS OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Kountouris, V
    Relakis, J.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S185 - S185
  • [4] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
    Strober, Bruce E.
    Pinter, Andreas
    Warren, Richard B.
    Blauvelt, Andrew
    Sebastian, Michael
    De Cuyper, Dirk
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    Gooderham, Melinda
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138
  • [5] BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIES
    Gottlieb, Alice B.
    Augustin, Matthias
    Lambert, Jo
    Pinter, Andreas
    Savage, Laura J.
    Tsai, Tsen-Fang
    Foley, Peter
    Paul, Carle
    Warham, Rhys
    Lambert, Jeremy
    Wiegratz, Susanne
    Stahle, Mona
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [6] ELEVATE: Study design of the observational study of bimekizumab in adult patients with moderate to severe plaque psoriasis
    Asadullah, Khusru
    Stavermann, Thomas
    Heidbrede, Tanja
    Schlueter, Kathrin
    Fierens, Frederik
    Thaci, Diamant
    von Kiedrowski, Ralph Michael
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 81 - 82
  • [7] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Christou, P.
    Relakis, J.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
  • [8] Bimekizumab in moderate-to-severe plaque psoriasis: population pharmacokinetic and pharmacodynamic relationships
    Vajjah, P.
    Acharya, C.
    Brekkan, A.
    Zamacona, M.
    Nemansky, M.
    Peterson, L.
    MacPherson, M.
    Oliver, R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E47 - E48
  • [9] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
    Blauvelt, Andrew
    Wu, Jashin J.
    Reich, Kristian
    Gooderham, Melinda
    Lebwohl, Mark
    White, Katy
    Cross, Nancy
    Cioffi, Christopher
    Papp, Kim A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
  • [10] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
    Wang, Yuqian
    Li, Sheng
    Bai, Juan
    Cai, Xiaoxuan
    Tang, Shunli
    Lin, Peiyi
    Sun, Qingmiao
    Qiao, Jianjun
    Fang, Hong
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
12345